Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — H1 2010 Earnings Presentation
12 slides from Novo Nordisk A/s Class B's earnings presentation, August 2010
Slide 1: Investor presentation First six months of 2010
Investor presentation Investor presentation First six months of 2010
Slide 2: Agenda
Investor presentation First six months of 2010 Slide no 2 Agenda Highlights for the first six months of 2010 by Lars Rebien Sørensen, CEO EU health care reforms and Victoza® launch update by Kåre Schultz, COO Recent development in clinical pipeline by Mads Krogsgaard Thomsen, CSO Financials and outl
Slide 3: Forward-looking statements
Investor presentation First six months of 2010 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company’s Annual Report 2009 and Form 20-F, both filed with the SEC in February 2010 as well as this d
Slide 4: Highlights and key events
Investor presentation First six months of 2010 Slide no 4 Highlights and key events Market development • Modern insulins drive robust sales growth of 14% (11% in local currencies) • North America and International Operations account for more than 80% of sales growth • Victoza® launched in Japan and
Slide 5: Limited financial impact for Novo Nordisk of announced health care reforms in Europe
Investor presentation First six months of 2010 Slide no 5 Limited financial impact for Novo Nordisk of announced health care reforms in Europe Germany: • Mandatory rebate for patent protected drugs increased from 6% to 16% • Price freeze based on 2009 prices • Free pricing restricted to first 12 mon
Slide 6: Encouraging US performance of Victoza®
Investor presentation First six months of 2010 Slide no 6 Encouraging US performance of Victoza® Victoza® is gradually expanding Distribution of previous treatment for the US GLP-1 market patients on Victoza® GLP-1 % of diabetes value market (right axis) 60 4% GLP-1 TRx scripts (1000’s) 50 Other 3%
Slide 7: First phase 3 trial confirms DegludecPlus' profile is effective, safe and convenient
Investor presentation First six months of 2010 Slide no 7 First phase 3 trial confirms DegludecPlus’ profile is effective, safe and convenient Trial design: Trial design Trial results • Controlled, open label, treat-to-target trial • People with type 1 diabetes randomised for 6 months to either: • D
Slide 8: Clinical proof of concept established for recombinant factor VIIa analogue
Investor presentation First six months of 2010 Slide no 8 Clinical proof of concept established for recombinant factor VIIa analogue Trial design: • Randomised, double-blinded, controlled, dose-escalation phase 2 trial evaluating the safety, pharmacokinetics and efficacy of NN1731, an ultra fast-act
Slide 9: Financial results
Investor presentation First six months of 2010 Slide no 9 Financial results DKK million H1 2010 H1 2009 change Sales 29,068 25,499 14% Gross profit 23,409 20,381 15% Gross margin 80.5% 79.9% Sales and distribution costs 8,348 7,681 9% Percent of sales 28.7% 30.1% Research and development costs 4,565
Slide 10: Financial guidance for 2010
Investor presentation First six months of 2010 Slide no 10 Financial guidance for 2010 • Sales growth expectations: Key currency rates • Now in the range of 9-10% in local currencies DKK 2009 2010 Current per 100 average average* rate • Now around 6 percentage points higher as reported USD 536 565 5
Slide 11: Closing remarks
Investor presentation First six months of 2010 Slide no 11 Closing remarks Solid market performance Promising pipeline • 10% annual diabetes market growth • GLP-1 portfolio offers opportunity to driven by diabetes prevalence expand within early stage type 2 diabetes and establish presence • 51% insu
Slide 12: Investor information
Investor presentation First six months of 2010 Slide no 12 Investor information Share information Investor Relations contacts Novo Nordisk’s B shares are listed on the Novo Nordisk A/S stock exchange in Copenhagen. Its ADRs are Investor Relations Novo Allé, DK-2880 Bagsværd listed on the New York St